1
|
Deng Y, Zhang J, Sun X, Li L, Zhou M, Liu S, Chen F, Pan C, Yu Z, Li M, Zhong W, Zeng M. Potent gene delivery from fluorinated poly(β-amino ester) in adhesive and suspension difficult-to-transfect cells for apoptosis and ferroptosis. J Control Release 2023; 363:597-605. [PMID: 37793484 DOI: 10.1016/j.jconrel.2023.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 09/19/2023] [Accepted: 10/01/2023] [Indexed: 10/06/2023]
Abstract
Tremendous efforts have been made to improve polymeric property in gene delivery performances, especially when obstacle of transferring gene construct into difficult-to-transfect cells occurs. Innovations in the area of fluorination and fluorinated compounds with biomedical potential in medicinal chemistry are believed to assist in the development of new therapeutics. Fluorine modified polymers have shown to navigate the gene transfection cellular barriers and promoted the transfection outcomes. Gene transfer into some liver cancer cells and human leukemia cells has always been a challenge. Here, by facile incorporation of a fluorine containing amine monomer, 1H,1H-undecafluorohexylamine, fluorinated poly(β-amino ester) (FPAE) was synthesized to significantly improve the transfection performance, achieving high transfection efficiency of 87% and 55% in two representative difficult-to-transfect cells, HepG2 and Molt-4, which were cultured in adhesive and suspension condition, respectively. However, the potency of Lipofectamine 3000 was very limited. More importantly, functional studies revealed that FPAE can dramatically outperform Lipofectamine 3000 in delivering Bcl-xL and PKCβII to either provide the protection against apoptosis or promote the ferroptosis in HepG2 cells. This work facilitates gene therapies by overcoming biological barriers for targeting difficult-to-transfect cells and disease models when medically necessary.
Collapse
Affiliation(s)
- Yihui Deng
- Central Laboratory of the First Affiliated Hospital of Jinan University, Guangzhou Overseas Chinese Hospital, Jinan University, Guangzhou 510630, China
| | - Jing Zhang
- State Key Laboratory of Materials-Oriented Chemical Engineering, College of Chemical Engineering, Nanjing Tech University, Nanjing 211816, China
| | - Ximeng Sun
- State Key Laboratory of Materials-Oriented Chemical Engineering, College of Chemical Engineering, Nanjing Tech University, Nanjing 211816, China
| | - Liangtao Li
- Department of Dermatology, The First Affiliated Hospital of Jinan University, Guangzhou Overseas Chinese Hospital, Jinan University, Guangzhou 510630, China
| | - Mandi Zhou
- Department of Dermatology, The First Affiliated Hospital of Jinan University, Guangzhou Overseas Chinese Hospital, Jinan University, Guangzhou 510630, China
| | - Shuang Liu
- Ministry of Education (MOE) Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou 510632, China
| | - Fuying Chen
- Department of Dermatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
| | - Chaolan Pan
- Dermatology Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
| | - Ziyi Yu
- State Key Laboratory of Materials-Oriented Chemical Engineering, College of Chemical Engineering, Nanjing Tech University, Nanjing 211816, China
| | - Ming Li
- Department of Dermatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China
| | - Wenbin Zhong
- Ministry of Education (MOE) Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou 510632, China
| | - Ming Zeng
- Department of Dermatology, The First Affiliated Hospital of Jinan University, Guangzhou Overseas Chinese Hospital, Jinan University, Guangzhou 510630, China; Department of Dermatology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China.
| |
Collapse
|
2
|
Del Castillo GFD, Kyriakidou M, Adali Z, Xiong K, Hailes RLN, Dahlin A. Electrically Switchable Polymer Brushes for Protein Capture and Release in Biological Environments. Angew Chem Int Ed Engl 2022; 61:e202115745. [PMID: 35289480 PMCID: PMC9311814 DOI: 10.1002/anie.202115745] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Indexed: 12/25/2022]
Abstract
Interfaces functionalized with polymers are known for providing excellent resistance towards biomolecular adsorption and for their ability to bind high amounts of protein while preserving their structure. However, making an interface that switches between these two states has proven challenging and concepts to date rely on changes in the physiochemical environment, which is static in biological systems. Here we present the first interface that can be electrically switched between a high‐capacity (>1 μg cm−2) multilayer protein binding state and a completely non‐fouling state (no detectable adsorption). Switching is possible over multiple cycles without any regeneration. Importantly, switching works even when the interface is in direct contact with biological fluids and a buffered environment. The technology offers many applications such as zero fouling on demand, patterning or separation of proteins as well as controlled release of biologics in a physiological environment, showing high potential for future drug delivery in vivo.
Collapse
Affiliation(s)
| | - Maria Kyriakidou
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemigården 4, 41296, Göteborg, Sweden
| | - Zeynep Adali
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemigården 4, 41296, Göteborg, Sweden
| | - Kunli Xiong
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemigården 4, 41296, Göteborg, Sweden
| | - Rebekah L N Hailes
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemigården 4, 41296, Göteborg, Sweden
| | - Andreas Dahlin
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemigården 4, 41296, Göteborg, Sweden
| |
Collapse
|
3
|
Castillo GF, Kyriakidou M, Adali Z, Xiong K, Hailes RLN, Dahlin A. Electrically Switchable Polymer Brushes for Protein Capture and Release in Biological Environments**. Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202115745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Gustav Ferrand‐Drake Castillo
- Department of Chemistry and Chemical Engineering Chalmers University of Technology Kemigården 4 41296 Göteborg Sweden
| | - Maria Kyriakidou
- Department of Chemistry and Chemical Engineering Chalmers University of Technology Kemigården 4 41296 Göteborg Sweden
| | - Zeynep Adali
- Department of Chemistry and Chemical Engineering Chalmers University of Technology Kemigården 4 41296 Göteborg Sweden
| | - Kunli Xiong
- Department of Chemistry and Chemical Engineering Chalmers University of Technology Kemigården 4 41296 Göteborg Sweden
| | - Rebekah L. N. Hailes
- Department of Chemistry and Chemical Engineering Chalmers University of Technology Kemigården 4 41296 Göteborg Sweden
| | - Andreas Dahlin
- Department of Chemistry and Chemical Engineering Chalmers University of Technology Kemigården 4 41296 Göteborg Sweden
| |
Collapse
|
4
|
Kumar R, Santa Chalarca CF, Bockman MR, Bruggen CV, Grimme CJ, Dalal RJ, Hanson MG, Hexum JK, Reineke TM. Polymeric Delivery of Therapeutic Nucleic Acids. Chem Rev 2021; 121:11527-11652. [PMID: 33939409 DOI: 10.1021/acs.chemrev.0c00997] [Citation(s) in RCA: 128] [Impact Index Per Article: 42.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The advent of genome editing has transformed the therapeutic landscape for several debilitating diseases, and the clinical outlook for gene therapeutics has never been more promising. The therapeutic potential of nucleic acids has been limited by a reliance on engineered viral vectors for delivery. Chemically defined polymers can remediate technological, regulatory, and clinical challenges associated with viral modes of gene delivery. Because of their scalability, versatility, and exquisite tunability, polymers are ideal biomaterial platforms for delivering nucleic acid payloads efficiently while minimizing immune response and cellular toxicity. While polymeric gene delivery has progressed significantly in the past four decades, clinical translation of polymeric vehicles faces several formidable challenges. The aim of our Account is to illustrate diverse concepts in designing polymeric vectors towards meeting therapeutic goals of in vivo and ex vivo gene therapy. Here, we highlight several classes of polymers employed in gene delivery and summarize the recent work on understanding the contributions of chemical and architectural design parameters. We touch upon characterization methods used to visualize and understand events transpiring at the interfaces between polymer, nucleic acids, and the physiological environment. We conclude that interdisciplinary approaches and methodologies motivated by fundamental questions are key to designing high-performing polymeric vehicles for gene therapy.
Collapse
Affiliation(s)
- Ramya Kumar
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | | | - Matthew R Bockman
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Craig Van Bruggen
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Christian J Grimme
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Rishad J Dalal
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Mckenna G Hanson
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Joseph K Hexum
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Theresa M Reineke
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| |
Collapse
|
5
|
Muhammad K, Zhao J, Ullah I, Guo J, Ren XK, Feng Y. Ligand targeting and peptide functionalized polymers as non-viral carriers for gene therapy. Biomater Sci 2020; 8:64-83. [DOI: 10.1039/c9bm01112a] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Ligand targeting and peptide functionalized polymers serve as gene carriers for efficient gene delivery.
Collapse
Affiliation(s)
- Khan Muhammad
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300350
- P. R. China
| | - Jing Zhao
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300350
- P. R. China
| | - Ihsan Ullah
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300350
- P. R. China
| | - Jintang Guo
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300350
- P. R. China
- Collaborative Innovation Center of Chemical Science and Chemical Engineering (Tianjin)
| | - Xiang-kui Ren
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300350
- P. R. China
- Collaborative Innovation Center of Chemical Science and Chemical Engineering (Tianjin)
| | - Yakai Feng
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300350
- P. R. China
- Collaborative Innovation Center of Chemical Science and Chemical Engineering (Tianjin)
| |
Collapse
|
6
|
Elzahhar P, Belal ASF, Elamrawy F, Helal NA, Nounou MI. Bioconjugation in Drug Delivery: Practical Perspectives and Future Perceptions. Methods Mol Biol 2019; 2000:125-182. [PMID: 31148014 DOI: 10.1007/978-1-4939-9516-5_11] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
For the past three decades, pharmaceutical research has been mainly converging to novel carrier systems and nanoparticulate colloidal technologies for drug delivery, such as nanoparticles, nanospheres, vesicular systems, liposomes, or nanocapsules to impart novel functions and targeting abilities. Such technologies opened the gate towards more sophisticated and effective multi-acting platform(s) which can offer site-targeting, imaging, and treatment using a single multifunctional system. Unfortunately, such technologies faced major intrinsic hurdles including high cost, low stability profile, short shelf-life, and poor reproducibility across and within production batches leading to harsh bench-to-bedside transformation.Currently, pharmaceutical industry along with academic research is investing heavily in bioconjugate structures as an appealing and advantageous alternative to nanoparticulate delivery systems with all its flexible benefits when it comes to custom design and tailor grafting along with avoiding most of its shortcomings. Bioconjugation is a ubiquitous technique that finds a multitude of applications in different branches of life sciences, including drug and gene delivery applications, biological assays, imaging, and biosensing.Bioconjugation is simple, easy, and generally a one-step drug (active pharmaceutical ingredient) conjugation, using various smart biocompatible, bioreducible, or biodegradable linkers, to targeting agents, PEG layer, or another drug. In this chapter, the different types of bioconjugates, the techniques used throughout the course of their synthesis and characterization, as well as the well-established synthetic approaches used for their formulation are presented. In addition, some exemplary representatives are outlined with greater emphasis on the practical tips and tricks of the most prominent techniques such as click chemistry, carbodiimide coupling, and avidin-biotin system.
Collapse
Affiliation(s)
- Perihan Elzahhar
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
| | - Ahmed S F Belal
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
| | - Fatema Elamrawy
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
| | - Nada A Helal
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
| | - Mohamed Ismail Nounou
- Department of Pharmaceutical Sciences, School of Pharmacy & Physician Assistant Studies (SOPPAS), University of Saint Joseph (USJ), Hartford, CT, USA.
| |
Collapse
|
7
|
Molla MR, Levkin PA. Combinatorial Approach to Nanoarchitectonics for Nonviral Delivery of Nucleic Acids. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2016; 28:1159-1175. [PMID: 26608939 DOI: 10.1002/adma.201502888] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 09/01/2015] [Indexed: 06/05/2023]
Abstract
Nanoparticles based on cationic polymers, lipids or lipidoids are of great interest in the field of gene delivery applications. The research on these nanosystems is rapidly growing as they hold promise to treat wide variety of human diseases ranging from viral infections to genetic disorders and cancer. Recently, combinatorial design principles have been adopted for rapid generation of large numbers of chemically diverse polymers and lipids capable of forming multifunctional nanocarriers for the use in gene delivery applications. At the same time, current high-throughput screening systems as well as convenient cell assays and readout techniques allow for fast evaluation of cell transfection efficiencies and toxicities of libraries of novel gene delivery agents. This allows for a rapid evaluation of structure-function relationship as well as identification of novel efficient nanocarriers for cell transfection and gene therapy. Here, the recent contribution of high-throughput synthesis to the development of novel nanocarriers for gene delivery applications is described.
Collapse
Affiliation(s)
- Mijanur Rahaman Molla
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
| | - Pavel A Levkin
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
- University of Heidelberg, Department of Applied Physical Chemistry, 69120, Heidelberg, Germany
| |
Collapse
|
8
|
Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee A. Non-viral gene therapy: Gains and challenges of non-invasive administration methods. J Control Release 2015; 240:165-190. [PMID: 26686079 DOI: 10.1016/j.jconrel.2015.12.012] [Citation(s) in RCA: 149] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Revised: 11/26/2015] [Accepted: 12/09/2015] [Indexed: 12/20/2022]
Abstract
Gene therapy is becoming an influential part of the rapidly increasing armamentarium of biopharmaceuticals for improving health and combating diseases. Currently, three gene therapy treatments are approved by regulatory agencies. While these treatments utilize viral vectors, non-viral alternative technologies are also being developed to improve the safety profile and manufacturability of gene carrier formulations. We present an overview of gene-based therapies focusing on non-viral gene delivery systems and the genetic therapeutic tools that will further revolutionize medical treatment with primary focus on the range and development of non-invasive delivery systems for dermal, transdermal, ocular and pulmonary administrations and perspectives on other administration methods such as intranasal, oral, buccal, vaginal, rectal and otic delivery.
Collapse
Affiliation(s)
- Marianna Foldvari
- School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Bioengineering and Biotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada.
| | - Ding Wen Chen
- School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Bioengineering and Biotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
| | - Nafiseh Nafissi
- School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Bioengineering and Biotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
| | - Daniella Calderon
- School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Bioengineering and Biotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
| | - Lokesh Narsineni
- School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Bioengineering and Biotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
| | - Amirreza Rafiee
- School of Pharmacy, Waterloo Institute of Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Bioengineering and Biotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
| |
Collapse
|
9
|
Lächelt U, Wagner E. Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). Chem Rev 2015; 115:11043-78. [DOI: 10.1021/cr5006793] [Citation(s) in RCA: 418] [Impact Index Per Article: 46.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Ulrich Lächelt
- Pharmaceutical
Biotechnology, Department of Pharmacy, Ludwig Maximilians Universität, 81377 Munich, Germany
- Nanosystems
Initiative
Munich (NIM), 80799 Munich, Germany
| | - Ernst Wagner
- Pharmaceutical
Biotechnology, Department of Pharmacy, Ludwig Maximilians Universität, 81377 Munich, Germany
- Nanosystems
Initiative
Munich (NIM), 80799 Munich, Germany
| |
Collapse
|
10
|
Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia. MOLECULAR THERAPY. NUCLEIC ACIDS 2015; 4:e240. [DOI: 10.1038/mtna.2015.13] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Accepted: 03/26/2015] [Indexed: 02/08/2023]
|
11
|
Yata T, Lee KY, Dharakul T, Songsivilai S, Bismarck A, Mintz PJ, Hajitou A. Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery. MOLECULAR THERAPY-NUCLEIC ACIDS 2014; 3:e185. [PMID: 25118171 PMCID: PMC4221597 DOI: 10.1038/mtna.2014.37] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Accepted: 06/24/2014] [Indexed: 02/07/2023]
Abstract
Developing nanomaterials that are effective, safe, and selective for gene transfer applications is challenging. Bacteriophages (phage), viruses that infect bacteria only, have shown promise for targeted gene transfer applications. Unfortunately, limited progress has been achieved in improving their potential to overcome mammalian cellular barriers. We hypothesized that chemical modification of the bacteriophage capsid could be applied to improve targeted gene delivery by phage vectors into mammalian cells. Here, we introduce a novel hybrid system consisting of two classes of nanomaterial systems, cationic polymers and M13 bacteriophage virus particles genetically engineered to display a tumor-targeting ligand and carry a transgene cassette. We demonstrate that the phage complex with cationic polymers generates positively charged phage and large aggregates that show enhanced cell surface attachment, buffering capacity, and improved transgene expression while retaining cell type specificity. Moreover, phage/polymer complexes carrying a therapeutic gene achieve greater cancer cell killing than phage alone. This new class of hybrid nanomaterial platform can advance targeted gene delivery applications by bacteriophage.
Collapse
Affiliation(s)
- Teerapong Yata
- Phage Therapy Group, Department of Medicine, Imperial College London, London, UK
| | - Koon-Yang Lee
- Polymers and Composites Engineering (PaCE) Group, Department of Chemical Engineering, Imperial College London, London, UK
| | - Tararaj Dharakul
- National Nanotechnology Center, National Science and Technology Development Agency, Khlong Luang Pathumthani, Thailand
| | - Sirirurg Songsivilai
- National Nanotechnology Center, National Science and Technology Development Agency, Khlong Luang Pathumthani, Thailand
| | - Alexander Bismarck
- Polymers and Composites Engineering (PaCE) Group, Department of Chemical Engineering, Imperial College London, London, UK
| | - Paul J Mintz
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Amin Hajitou
- Phage Therapy Group, Department of Medicine, Imperial College London, London, UK
| |
Collapse
|
12
|
Rahikkala A, Junnila S, Vartiainen V, Ruokolainen J, Ikkala O, Kauppinen E, Raula J. Polypeptide-based aerosol nanoparticles: self-assembly and control of conformation by solvent and thermal annealing. Biomacromolecules 2014; 15:2607-15. [PMID: 24848300 DOI: 10.1021/bm500704e] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Nanoconfined self-assemblies within aerosol nanoparticles and control of the secondary structures are shown here upon ionically complexing poly(L-lysine) (PLL) with dodecylbenzenesulfonic acid (DBSA) surfactant and using solvents chloroform, 1-propanol, or dimethylformamide. Different solvent volatilities and drying temperatures allowed tuning the kinetics of morphology formation. The supramolecular self-assembly and morphology were studied using cryo-TEM and SEM, and the secondary structures, using FT-IR. Highly volatile chloroform led to the major fraction of α-helical conformation of PLL(DBSA), whereas less volatile solvents or higher drying temperatures led to the increasing fraction of β-sheets. Added drugs budesonide and ketoprofen prevented β-sheet formation and studied PLL(DBSA)-drug nanoparticles were in the α-helical conformation. Preliminary studies showed that ketoprofen released with a slower rate than budesonide which was hypothesized to result from different localization of drugs within the PLL(DBSA) nanoparticles. These results instruct to prepare polypeptide aerosol nanoparticles with internal self-assembled structures and to control the secondary structures by aerosol solvent annealing, which we foresee to be useful, e.g., toward controlling the release of poorly soluble drug molecules.
Collapse
Affiliation(s)
- Antti Rahikkala
- Department of Applied Physics, Aalto University School of Science , P.O. Box 15100, FIN-00076 Aalto, Espoo, Finland
| | | | | | | | | | | | | |
Collapse
|
13
|
A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy. Cancer Gene Ther 2012; 19:741-8. [PMID: 23018622 DOI: 10.1038/cgt.2012.64] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The development of effective treatments that enable many patients suffering from cancer to be successfully cured is highly demanded. Angiogenesis, which is a process for the formation of new capillary blood vessels, has a crucial role in solid tumor progression and the development of metastasis. Antiangiogenic therapy designed to prevent tumor angiogenesis, thereby arresting the growth or spread of tumors, has emerged as a non-invasive and safe option for cancer treatment. Due to the fact that integrin receptors are overexpressed on the surface of angiogenic endothelial cells, various strategies have been made to develop targeted delivery systems for cancer gene therapy utilizing integrin-targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence. The aim of this review is to summarize the progress and prospect of RGD-functionalized nonviral vectors toward targeted delivery of genetic materials in order to achieve an efficient therapeutic outcome for cancer gene therapy, including antiangiogenic therapy.
Collapse
|
14
|
Use of the JL1 epitope, which encompasses the nonglycosylation site of CD43, as a marker of immature/neoplastic Langerhans cells. Am J Surg Pathol 2012; 36:1150-7. [PMID: 22790855 DOI: 10.1097/pas.0b013e31825b9914] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Langerhans cell histiocytosis (LCH) is the collective designation for a group of proliferative disorders of antigen-presenting cells in the epidermis. Over the past several decades, the etiology of LCH has been a controversial issue, particularly with respect to the pathologic process, that is, whether it is a neoplastic or inflammatory process. Recently, it was reported that the JL1 epitope, which encompasses the nonglycosylation site of CD43, is only exposed in the precursor stages of hematopoietic cells or in neoplastic conditions. We sought to investigate the possible utility of the JL1 monoclonal antibody as a diagnostic marker of LCH. In this study, we compared the staining characteristics of antibodies against the JL1 epitope with those of langerin and CD1a, which are widely used for the diagnosis of LCH. We found substantial differences in the staining patterns of these markers. The JL1 epitope could be bound by antibodies in cases of LCH and Langerhans cell (LC) sarcoma. In non-neoplastic lesions, JL1-positive LCs were found only in dermatitis, reflecting the immaturity of LCs in inflamed skin. However, anti-langerin antibodies were able to identify any form of LC, including those in normal skin, dermatitis, dermatopathic lymphadenopathy, and LCH. On the basis of these findings, we propose that the anti-JL1 antibody is a specific marker of immaturity, a feature that is shared in neoplastic LCs, and can be useful in the diagnosis of LCH.
Collapse
|
15
|
Samal SK, Dash M, Van Vlierberghe S, Kaplan DL, Chiellini E, van Blitterswijk C, Moroni L, Dubruel P. Cationic polymers and their therapeutic potential. Chem Soc Rev 2012; 41:7147-94. [PMID: 22885409 DOI: 10.1039/c2cs35094g] [Citation(s) in RCA: 459] [Impact Index Per Article: 38.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The last decade has witnessed enormous research focused on cationic polymers. Cationic polymers are the subject of intense research as non-viral gene delivery systems, due to their flexible properties, facile synthesis, robustness and proven gene delivery efficiency. Here, we review the most recent scientific advances in cationic polymers and their derivatives not only for gene delivery purposes but also for various alternative therapeutic applications. An overview of the synthesis and preparation of cationic polymers is provided along with their inherent bioactive and intrinsic therapeutic potential. In addition, cationic polymer based biomedical materials are covered. Major progress in the fields of drug and gene delivery as well as tissue engineering applications is summarized in the present review.
Collapse
Affiliation(s)
- Sangram Keshari Samal
- Polymer Chemistry & Biomaterials Research Group, Ghent University, Krijgslaan 281, S4-Bis, B-9000 Ghent, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Hu HM, Zhang X, Zhong NQ, Pan SR. Study on Galactose–Poly(Ethylene Glycol)–Poly(L-Lysine) as Novel Gene Vector for Targeting Hepatocytes In Vitro. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION 2012; 23:677-95. [PMID: 21375808 DOI: 10.1163/092050611x558297] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Hai-Mei Hu
- a Guang Dong Pharmaceutical University, Guangzhou 510006, P. R. China; The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, P. R. China.
| | - Xuan Zhang
- b The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, P. R. China; Shenzhen Mental Health Center, Shenzhen 518020, P. R. China
| | - Nv-Qi Zhong
- c School of Pharmaceutical Sciences, Sun Yet-sen University, Guangzhou 510080, P. R. China
| | - Shi-Rong Pan
- d The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, P. R. China
| |
Collapse
|
17
|
Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery. J Control Release 2012; 157:183-9. [DOI: 10.1016/j.jconrel.2011.08.026] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Accepted: 08/08/2011] [Indexed: 01/16/2023]
|
18
|
Jeon YK, Min HS, Lee YJ, Kang BH, Kim EJ, Park HJ, Bae Y, Lee HG, Park WS, Song HG, Jung KC, Park SH. Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia. Cancer Immunol Immunother 2011; 60:1697-706. [PMID: 21710258 PMCID: PMC11028941 DOI: 10.1007/s00262-011-1066-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Accepted: 06/14/2011] [Indexed: 02/02/2023]
Abstract
Previously, we developed a JL1 mouse monoclonal antibody that specifically recognizes the leukemic cells of T, B, and myeloid lineages, but not the peripheral blood cells and pluripotent hematopoietic stem cells. Here, we identified that JL1 mAb recognized a specific epitope of human CD43 and validated its potential as an anti-leukemic targeting agent. After the comprehensive screening of JL1 Ag in the human thymocyte cDNA library, multiple fusion gene constructs encoding human CD43 were generated to identify its specific epitope to JL1 antibody. JL1 antibody interacted with a developmentally regulated and non-glycosylated epitope of the human CD43 extracellular domain (AA 73-81, EGSPLWTSI). In an in vivo leukemia model using NOD/SCID mice injected with CCRF-CEM7 cells, JL1 antibody induced effective cytotoxicity in tumor cells and prolonged survival (p < 0.05). Saporin conjugation to JL1 antibody effectively depleted tumor cells in in vitro cytotoxic assays and also prolonged survival in a leukemic mouse model (p < 0.001). These preclinical results further support the therapeutic potential of the JL1 antibody in the management of acute leukemia.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/therapeutic use
- Blotting, Western
- Cell Separation
- Disease Models, Animal
- Epitopes, B-Lymphocyte/immunology
- Flow Cytometry
- Humans
- Leukemia, Biphenotypic, Acute/drug therapy
- Leukemia, Biphenotypic, Acute/immunology
- Leukosialin/immunology
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Real-Time Polymerase Chain Reaction
Collapse
Affiliation(s)
- Yoon Kyung Jeon
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
| | - Hye Sook Min
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Dinona Inc., Seoul, Korea
| | - Yoo Jeong Lee
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Byung Hyun Kang
- Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea
| | - Eun Ji Kim
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Hyo Jin Park
- Department of Pathology, Seoul National University Bundang Hospital, Bundang, Korea
| | - Youngmee Bae
- Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Hyun Gyu Lee
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Weon Seo Park
- Department of Pathology and Research Center for Hematopoietic Tumor, National Cancer Center, Goyang, Korea
| | - Hyung Geun Song
- Dinona Inc., Seoul, Korea
- Department of Pathology, Chungbuk National University, Cheongju, Korea
| | - Kyeong Cheon Jung
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Dinona Inc., Seoul, Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| | - Seong Hoe Park
- Department of Pathology, Seoul National University College of Medicine, Seoul, 110-799 Korea
- Graduate Program of Immunology, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
19
|
Wang F, Bai HR, Wang J, Bai YZ, Dou CW. Glioma Growth Inhibition In Vitro and In Vivo by Single Chain Variable Fragments of the Transferrin Receptor Conjugated to Survivin Small Interfering RNA. J Int Med Res 2011; 39:1701-12. [PMID: 22117970 DOI: 10.1177/147323001103900512] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Inhibition of survivin by small interfering RNA (siRNA) can delay glioma growth. To enhance the effect of survivin-siRNA on intercranial glioma, a conjugate of siRNA-survivin and single-chain variable fragment (scFv) of the transferrin receptor (TfR) was constructed and its effects assessed in vitro and in vivo. Survivin-siRNA and the survivin-siRNA/scFv-TfR conjugate were constructed and used successfully to inhibit glioma U87 cell proliferation and enhance apoptosis in vitro. The molecular constructs were administered to an established U87 orthotopic mouse model. Western blot analysis and immunohistochemistry of the glioma tissues showed that survivin protein levels were strongly suppressed by the survivin-siRNA/scFv-TfR conjugate in vivo. Furthermore, survivin-siRNA/scFv-TfR prolonged the survival time of mice more than survivin-siRNA. In conclusion, the survivin-siRNA/scFv-TfR conjugate efficiently enhanced the effects of survivin-siRNA on glioma suppression in vivo, confirming the applicability of antibody-targeted molecular therapies for treating human brain tumours.
Collapse
Affiliation(s)
- F Wang
- Department of Neurosurgery, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China
| | - H-R Bai
- Department of Forensic Medicine, Inner Mongolia Medical College, Hohhot, China
| | - J Wang
- Department of Microbiology, Inner Mongolia Medical College, Hohhot, China
| | - Y-Z Bai
- Department of Nuclear Magnetic Resonance, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China
| | - C-W Dou
- Department of Neurosurgery, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China
| |
Collapse
|
20
|
Expression of JL1 in Burkitt lymphoma is associated with improved overall survival. Virchows Arch 2011; 459:353-9. [PMID: 21814778 DOI: 10.1007/s00428-011-1134-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2011] [Revised: 07/07/2011] [Accepted: 07/19/2011] [Indexed: 10/17/2022]
Abstract
JL1 is a novel molecule expressed in the surface of hematopoietic precursor cells, but not on any other mature human tissue. Accordingly, JL1 is expressed in acute lymphoblastic leukemia (ALL) cells and can be used both for specific diagnosis and as a target for treatment. However, expression of JL1 by lymphomas has not been thoroughly assessed. Burkitt lymphoma is a potentially curable aggressive lymphoma, but prognostic markers that stratify risk have not been established. We therefore assayed JL1 expression in Burkitt lymphoma patients to assess its value as a prognostic marker for this disease. Tissue microarray blocks of formalin-fixed paraffin-embedded tissue samples from patients with Burkitt lymphoma and other B-cell lymphomas, at the Asan Medical Center and Seoul National University Hospital from January 1998 to December 2008 were immunohistochemically assayed using a mouse monoclonal antibody against JL1. We found that 30.2% of Burkitt lymphoma samples, but no other lymphoma samples, were positive for JL1. JL-1 expression was significantly correlated with patient survival (P = 0.022), but not with other clinical manifestations of the disease, with 91.6% of JL1-positive patients achieving complete remission in response to chemotherapy and 6.25% experiencing disease recurrence. JL1 positivity was significantly correlated with prolonged overall survival by both Kaplan-Meier survival (P = 0.035) and Cox proportional hazard model (P = 0.043) analysis. JL1 expression in Burkitt lymphoma was positively correlated with overall survival and better response to chemotherapy, suggesting that JL1 may be a prognostic marker for risk stratification in these patients.
Collapse
|
21
|
Ryu DW, Kim HA, Song H, Kim S, Lee M. Amphiphilic peptides with arginines and valines for the delivery of plasmid DNA. J Cell Biochem 2011; 112:1458-66. [DOI: 10.1002/jcb.23064] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
22
|
Kim J, Kim SW, Kim WJ. PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. Oligonucleotides 2011; 21:101-7. [PMID: 21375397 DOI: 10.1089/oli.2011.0278] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Tumor angiogenesis appears to be achieved by the expression of vascular endothelial growth factor (VEGF) within solid tumors that stimulate host vascular endothelial cell mitogenesis and possibly chemotaxis. VEGF's angiogenic actions are mediated through its high-affinity binding to 2 endothelium-specific receptor tyrosine kinase, Flt-1 (VEGFR1), and Flk-1/KDR (VEGFR2). RNA interference-mediated knockdown of protein expression at the messenger RNA level provides a new therapeutic strategy to overcome various diseases. To achieve high efficacy in RNA interference-mediated therapy, it is critical to develop an efficient delivering system to deliver small interference RNA (siRNA) into tissues or cells site-specifically. We previously reported an angiogenic endothelial cell-targeted polymeric gene carrier, PEI-g-PEG-RGD. This targeted carrier was developed by the conjugation of the ανβ3/ανβ5 integrin-binding RGD peptide (ACDCRGDCFC) to the cationic polymer, branched polyethylenimine, with a hydrophilic polyethylene glycol (PEG) spacer. In this study, we used PEI-g-PEG-RGD to deliver siRNA against VEGFR1 into tumor site. The physicochemical properties of PEI-g-PEG-RGD/siRNA complexes was evaluated. Further, tumor growth profile was also investigated after systemic administration of PEI-g-PEG-RGD/siRNA complexes.
Collapse
Affiliation(s)
- Jihoon Kim
- Department of Chemistry, BK School of Molecular Science, Polymer Research Institute, Pohang University of Science and Technology , Pohang, Korea
| | | | | |
Collapse
|
23
|
|
24
|
Lee CC, Grandinetti G, McLendon PM, Reineke TM. A Polycation Scaffold Presenting Tunable “Click” Sites: Conjugation to Carbohydrate Ligands and Examination of Hepatocyte-Targeted pDNA Delivery. Macromol Biosci 2010; 10:585-98. [DOI: 10.1002/mabi.200900431] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
25
|
Abstract
Hydrogel nanoparticles—also referred to as polymeric nanogels or macromolecular micelles—are emerging as promising drug carriers for therapeutic applications. These nanostructures hold versatility and properties suitable for the delivery of bioactive molecules, namely of biopharmaceuticals. This article reviews the latest developments in the use of self-assembled polymeric nanogels for drug delivery applications, including small molecular weight drugs, proteins, peptides, oligosaccharides, vaccines and nucleic acids. The materials and techniques used in the development of self-assembling nanogels are also described.
Collapse
|
26
|
Endogenous HIV-1 Vpr-mediated apoptosis and proteome alteration of human T-cell leukemia virus-1 transformed C8166 cells. Apoptosis 2010; 14:1212-26. [PMID: 19655254 DOI: 10.1007/s10495-009-0380-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
HIV-1 viral protein R (Vpr) can induce cell cycle arrest and cell death, and may be beneficial in cancer therapy to suppress malignantly proliferative cell types, such as adult T-cell leukemia (ATL) cells. In this study, we examined the feasibility of employing the HIV-vpr gene, via targeted gene transfer, as a potential new therapy to kill ATL cells. We infected C8166 cells with a recombinant adenovirus carrying both vpr and GFP genes (rAd-vpr), as well as the vector control virus (rAd-vector). G(2)/M phase cell cycle arrest was observed in the rAd-vpr infected cells. Typical characteristics of apoptosis were detected in rAd-vpr infected cells, including sub-diploid peak exhibition in DNA content assay, the Hoechst 33342 accumulation, apoptotic body formation, mitochondrial membrane potential and plasma membrane integrity loss. The proteomic assay revealed apoptosis related protein changes, exhibiting the regulation of caspase-3 activity indicator proteins (vimentin and Rho GDP-dissociation inhibitor 2), mitochondrial protein (prohibitin) and other regulatory proteins. In addition, the up-regulation of anti-inflammatory redox protein, thioredoxin, was identified in the rAd-vpr infected group. Further supporting these findings, the increase of caspase 3&7 activity in the rAd-vpr infected group was observed. In conclusion, endogenous Vpr is able to kill HTLV-1 transformed C8166 cells, and may avoid the risks of inducing severe inflammatory responses through apoptosis-inducing and anti-inflammatory activities.
Collapse
|
27
|
Zhao X, Pan F, Yaseen M, Lu JR. Molecular biophysics underlying gene delivery. ACTA ACUST UNITED AC 2010. [DOI: 10.1039/b903512p] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
28
|
Abstract
Cationic polymers have been chemically modified with a variety of targeting molecules such as peptides, proteins, antibodies, sugars and vitamins for targeted delivery of nucleic acid drugs to specific cells. Stimuli-sensitive polymers exhibiting different size, charge and conformation in response to physiological signals from specific cells have also been utilized for targeted delivery. To achieve target-specific delivery of nucleic acids, conjugation chemistry is critical to produce stable nanosized polyplexes tethered with cell-recognizable ligands for facile cellular uptake via a receptor-mediated endocytic pathway. In this review, synthetic strategies of functional cationic polymers with various targeting ligands are presented.
Collapse
Affiliation(s)
- Hyejung Mok
- Department of Biological Sciences and the Graduate Program of Nanoscience and Technology, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
| | | |
Collapse
|
29
|
Theoharis S, Krueger U, Tan PH, Haskard DO, Weber M, George AJ. Targeting gene delivery to activated vascular endothelium using anti E/P-Selectin antibody linked to PAMAM dendrimers. J Immunol Methods 2009; 343:79-90. [DOI: 10.1016/j.jim.2008.12.005] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2008] [Revised: 11/26/2008] [Accepted: 12/17/2008] [Indexed: 02/08/2023]
|
30
|
Affiliation(s)
| | - Eric E. Simanek
- Department of Chemistry, Texas A&M University, College Station, Texas 77843
| |
Collapse
|
31
|
Heparin-conjugated polyethylenimine for gene delivery. J Control Release 2008; 132:236-42. [DOI: 10.1016/j.jconrel.2008.05.017] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2008] [Revised: 05/16/2008] [Accepted: 05/18/2008] [Indexed: 11/23/2022]
|
32
|
|
33
|
Zugates GT, Tedford NC, Zumbuehl A, Jhunjhunwala S, Kang CS, Griffith LG, Lauffenburger DA, Langer R, Anderson DG. Gene Delivery Properties of End-Modified Poly(β-amino ester)s. Bioconjug Chem 2007; 18:1887-96. [DOI: 10.1021/bc7002082] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Gregory T. Zugates
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Nathan C. Tedford
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Andreas Zumbuehl
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Siddharth Jhunjhunwala
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Christina S. Kang
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Linda G. Griffith
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Douglas A. Lauffenburger
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Robert Langer
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| | - Daniel G. Anderson
- Department of Chemical Engineering, Biological Engineering Division, Department of Mechanical Engineering, and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
| |
Collapse
|
34
|
Kostiainen MA, Szilvay GR, Lehtinen J, Smith DK, Linder MB, Urtti A, Ikkala O. Precisely defined protein-polymer conjugates: construction of synthetic DNA binding domains on proteins by using multivalent dendrons. ACS NANO 2007; 1:103-113. [PMID: 19206526 DOI: 10.1021/nn700053y] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Nature has evolved proteins and enzymes to carry out a wide range of sophisticated tasks. Proteins modified with functional polymers possess many desirable physical and chemical properties and have applications in nanobiotechnology. Here we describe multivalent Newkome-type polyamine dendrons that function as synthetic DNA binding domains, which can be conjugated with proteins. These polyamine dendrons employ naturally occurring spermine surface groups to bind DNA with high affinity and are attached onto protein surfaces in a site-specific manner to yield well-defined one-to-one protein-polymer conjugates, where the number of dendrons and their attachment site on the protein surface are precisely known. This precise structure is achieved by using N-maleimido-core dendrons that selectively react via 1,4-conjugate addition with a single free thiol group on the protein surface--either Cys-34 of bovine serum albumin (BSA) or a genetically engineered cysteine mutant of Class II hydrophobin (HFBI). This reaction can be conducted in mild aqueous solutions (pH 7.2-7.4) and at ambient temperature, resulting in BSA- and HFBI-dendron conjugates. The protein-dendron conjugates constitute a specific biosynthetic diblock copolymer and bind DNA with high affinity, as shown by ethidium bromide displacement assay. Importantly, even the low-molecular-weight first-generation polyamine dendron (1 kDa) can bind a large BSA protein (66.4 kDa) to DNA with relatively good affinity. Preliminary gene transfection, cytotoxicity, and self-assembly studies establish the relevance of this methodology for in vitro applications, such as gene therapy and surface patterning. These results encourage further developments in protein-dendron block copolymer-like conjugates and will allow the advance of functional biomimetic nanoscale materials.
Collapse
Affiliation(s)
- Mauri A Kostiainen
- Department of Engineering, Physics, and Mathematics and Center for New Materials, Helsinki University of Technology, P.O. Box 2200, 02015 HUT, Espoo, Finland.
| | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Theoharis S, Manunta M, Tan PH. Gene delivery to vascular endothelium using chemical vectors: implications for cardiovascular gene therapy. Expert Opin Biol Ther 2007; 7:627-43. [PMID: 17477801 DOI: 10.1517/14712598.7.5.627] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The vascular endothelium is an attractive target for gene therapy because of its accessibility and its importance in the pathophysiology of a wide range of cardiovascular conditions. In general, viral methods have been shown to be very effective at delivering genes to endothelium. The immunogenicity and pathogenicity associated with viral vectors have led increased efforts to seek alternative means of 'ferrying' therapeutic genes to endothelium or to decrease the short-comings of viral vectors. This paper reviews developments in non-viral technology. In addition, discussion also covers the mechanisms whereby existing chemical vectors deliver DNA to cells. Understanding the pathways of vector internalisation and intracellular traffic is important in developing strategies to improve vector technology. The authors propose that the chemical vector may represent a robust and versatile technology to 'ferry' therapeutic genes to vascular endothelium in order to modify the endothelial dysfunction associated with many cardiovascular diseases.
Collapse
Affiliation(s)
- Stefanos Theoharis
- Imperial College London, Department of Immunology, Division of Medicine, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
| | | | | |
Collapse
|
37
|
Lavigne MD, Górecki DC. Emerging vectors and targeting methods for nonviral gene therapy. Expert Opin Emerg Drugs 2006; 11:541-57. [PMID: 16939390 DOI: 10.1517/14728214.11.3.541] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Until recently, nonviral vectors were outside the mainstream of gene transfer technology. Recent problems in clinical trials using viral vectors renewed interest in these methods. The clinical usefulness of nonviral methods is still hindered by their relatively low gene delivery/transgene expression efficiencies. Vectors must navigate a series of obstacles before the therapeutic gene can be expressed. This review considers these barriers and the properties of components of nonviral vectors that are essential for nucleic acid transfer. Although developments of new physical methods (hydrodynamic delivery, ultrasound, electroporation) have made a significant impact on gene transfer efficiency, various chemical carriers (lipids and polymers) have been shown to achieve high-level gene delivery and functional expression. Success of nonviral gene targeting will depend not only on the efficacy, but also safety of this methodology, and this aspect is also discussed. Understanding problems associated with nonviral targeting can also help in designing better viral vectors. In fact, interplay between viral and nonviral technologies should lead to a continued refinement of both methodologies.
Collapse
Affiliation(s)
- Matthieu D Lavigne
- University of Portsmouth, School of Pharmacy and Biomedical Sciences, St. Michael's Building, White Swan Road, Portsmouth, UK
| | | |
Collapse
|
38
|
Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23:1417-50. [PMID: 16779701 DOI: 10.1007/s11095-006-0284-8] [Citation(s) in RCA: 511] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2005] [Accepted: 03/01/2006] [Indexed: 01/19/2023]
Abstract
The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the "magic bullet" proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.
Collapse
Affiliation(s)
- Patrick Couvreur
- Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Université de Paris Sud, 5 Rue J.B. Clément, 92 296, Chatenay-Malabry Cedex, France
| | | |
Collapse
|
39
|
. SNU, . KI. Cationic Polymers and its Uses in Non-viral Gene Delivery Systems: A Conceptual Research. ACTA ACUST UNITED AC 2006. [DOI: 10.3923/tmr.2006.86.99] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
40
|
Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH, Kim SW. Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release 2006; 107:562-70. [PMID: 16139384 DOI: 10.1016/j.jconrel.2005.07.010] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2005] [Revised: 07/01/2005] [Accepted: 07/07/2005] [Indexed: 10/25/2022]
Abstract
An islet cell targeting polymeric gene carrier was synthesized by conjugating anti-GAD Fab' fragment to PEI via PEG linker (PEI-PEG-Fab'). The Fab' fragment was prepared from a murine monoclonal antibody against glutamic acid decarboxylase (GAD), which has been identified as one of the major auto-antigens expressed in islet cells, and used as a targeting moiety for islet cell targeting. The electrophoretic migration of plasmid DNA (pCMVLuc)/PEI-PEG-Fab' complexes in agarose gel was completely retarded above the N/P ratio of 2. The complexes demonstrated a size of 100-275 nm with an almost neutral surface charge. Confocal microscopy revealed that the PEI-PEG-Fab' complexes showed much higher cellular binding and uptake efficiency compared to PEI-PEG complexes. The PEI-PEG-Fab' showed about 10-fold higher transfection efficiency (relative luciferase activity) than PEI-PEG in GAD-expressing mouse insulinoma cells (MIN6), however the transfection efficiency of PEI-PEG-Fab' reduced to that of PEI-PEG in GAD negative cells (293) and in the presence of competitive free Fab'. Considering the neutral surface charge of its complexes with DNA, and selectivity toward the islet cells expressing a specific antigen, the PEI-PEG-Fab' conjugate could be thought as a potential candidate of the systemic gene therapy for the treatment of type I diabetes.
Collapse
Affiliation(s)
- Ji Hoon Jeong
- CCCD/Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | | | | | | | | | | | | |
Collapse
|
41
|
Cook SE, Park IK, Kim EM, Jeong HJ, Park TG, Choi YJ, Akaike T, Cho CS. Galactosylated polyethylenimine-graft-poly(vinyl pyrrolidone) as a hepatocyte-targeting gene carrier. J Control Release 2005; 105:151-63. [PMID: 15878633 DOI: 10.1016/j.jconrel.2005.03.011] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2004] [Revised: 03/25/2005] [Accepted: 03/28/2005] [Indexed: 11/20/2022]
Abstract
Polyethylenimine (PEI) has been used for the gene delivery system in vitro and in vivo since it has high transfection efficiency owing to proton buffer capacity. However, the use of PEI for gene delivery is limited due to cytotoxicity, non-specificity and unnecessary interaction with serum components. To overcome cytotoxicity and non-specificity, PEI was coupled with poly(vinyl pyrrolidone) (PVP) as the hydrophilic group to reduce cytotoxicity and lactose bearing galactose group for hepatocyte targeting. The galactosylated-PEI-graft-PVP (GPP) was complexed with DNA, and GPP/DNA complexes were characterized. GPP showed good DNA binding ability, high protection of DNA from nuclease attack. The sizes of DNA complexes show tendency to decrease with an increase of charge ratio and had a minimum value around 59 nm at the charge ratio of 40 for the GPP-1/DNA complex (PVP content: 4.1 mol%). The GPP showed low cytotoxicity. And GPP/DNA complexes were mediated by asialoglycoprotein receptors (ASGP-R)-mediated endocytosis. Also, the transfection efficiency of GPP-1/DNA complex at charge ratio of 40 in the HepG2 was higher than that of PEI/DNA one.
Collapse
Affiliation(s)
- Seung Eun Cook
- School of Agricultural Biotechnology, Seoul National University, Seoul 151-742, South Korea
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005; 4:581-93. [PMID: 16052241 DOI: 10.1038/nrd1775] [Citation(s) in RCA: 1893] [Impact Index Per Article: 99.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The lack of safe and efficient gene-delivery methods is a limiting obstacle to human gene therapy. Synthetic gene-delivery agents, although safer than recombinant viruses, generally do not possess the required efficacy. In recent years, a variety of effective polymers have been designed specifically for gene delivery, and much has been learned about their structure-function relationships. With the growing understanding of polymer gene-delivery mechanisms and continued efforts of creative polymer chemists, it is likely that polymer-based gene-delivery systems will become an important tool for human gene therapy.
Collapse
Affiliation(s)
- Daniel W Pack
- Department of Chemical and Biomolecular Engineering, University of Illinois, Box C-3, 600 South Mathews Avenue, Urbana, IL 61801, USA.
| | | | | | | |
Collapse
|
43
|
Abstract
Over the past decade, significant research has been done in the area of polymer-mediated gene delivery. Synthesis of new polymers and modifications to existing polymers has resulted in polyplexes with improved in vitro and in vivo transfection efficiencies. Targeting has been an important aspect of this research, and various strategies for obtaining selective and enhanced gene delivery to the target site have been evaluated. This review covers the different aspects involved in polyplex targeting. Development of targeted polyplexes involves a careful consideration of the target site, the targeting ligand and the physicochemical properties of the polyplex itself. The need to redirect the polyplexes by using the 'shield and target' approach by reducing nonspecific interactions with negatively charged components, while conferring specificity by incorporating targeting ligands, is discussed. Basic chemistry involved in modifying polymers is covered and examples of targeting strategies used for tissue-specific gene delivery are discussed. Targeting is also discussed in the broader context of developing safe and effective polymeric vectors for in vivo gene delivery. Maximum benefit of targeting can be obtained when it is used as part of a multi-functional complex containing elements designed to improve gene delivery and reduce overall toxicity of the polyplex.
Collapse
Affiliation(s)
- Jeffery A Hughes
- University of Florida, Department of Pharmaceutics, College of Pharmacy, Gainesville, Florida, USA
| | | |
Collapse
|
44
|
Abstract
Nucleic acid delivery has many applications in basic science, biotechnology, agriculture, and medicine. One of the main applications is DNA or RNA delivery for gene therapy purposes. Gene therapy, an approach for treatment or prevention of diseases associated with defective gene expression, involves the insertion of a therapeutic gene into cells, followed by expression and production of the required proteins. This approach enables replacement of damaged genes or expression inhibition of undesired genes. Following two decades of research, there are two major methods for delivery of genes. The first method, considered the dominant approach, utilizes viral vectors and is generally an efficient tool of transfection. Attempts, however, to resolve drawbacks related with viral vectors (e.g., high risk of mutagenicity, immunogenicity, low production yield, limited gene size, etc.), led to the development of an alternative method, which makes use of non-viral vectors. This review describes non-viral gene delivery vectors, termed "self-assembled" systems, and are based on cationic molecules, which form spontaneous complexes with negatively charged nucleic acids. It introduces the most important cationic polymers used for gene delivery. A transition from in vitro to in vivo gene delivery is also presented, with an emphasis on the obstacles to achieve successful transfection in vivo.
Collapse
Affiliation(s)
- H. Eliyahu
- Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Jerusalem, Israel
- Laboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University – Hadassah Medical School, Jerusalem, Israel
| | - Y. Barenholz
- Laboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University – Hadassah Medical School, Jerusalem, Israel
| | - A. J. Domb
- Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Jerusalem, Israel
| |
Collapse
|
45
|
Roth CM, Sundaram S. Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways. Annu Rev Biomed Eng 2004; 6:397-426. [PMID: 15255775 DOI: 10.1146/annurev.bioeng.6.040803.140203] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Significant progress has been made in the area of nonviral gene delivery to date. Yet, synthetic vectors remain less efficient by orders of magnitude than their viral counterparts. Research continues toward unraveling and overcoming various barriers to the efficient delivery of DNA, whether in plasmid form encoding a gene or as an oligonucleotide for the selective inhibition of target gene expression. Novel components for overcoming these hurdles are continually being incorporated into the design of synthetic vectors, leading to increasingly more virus-like particles. Despite these advances, general principles defining the design of synthetic vectors are yet to be developed fully. A more quantitative analysis of the cellular uptake and intracellular processing of these vectors is required for the rational manipulation of vector design. Mathematical frameworks with a more conceptual basis will help obtain an integrated perspective on these complex systems. In this review, we critically examine the progress made toward the improved design of synthetic vectors by the strategic exploitation of intracellular mechanisms and explore newer possibilities to overcome obstacles in the practical realization of this field.
Collapse
Affiliation(s)
- Charles M Roth
- Department of Chemical and Biochemical Engineering, Rutgers University, Piscataway, New Jersey 08854, USA.
| | | |
Collapse
|
46
|
Abstract
The main objective in gene therapy is the development of efficient, non-toxic gene carriers that can encapsulate and deliver foreign genetic materials into specific cell types such as cancerous cells. During the past two decades, enormous research in the area of gene delivery has been conducted worldwide, in particular for cancer gene therapy application. Viral vectors are biological systems derived from naturally evolved viruses capable of transferring their genetic materials into the host cells. Many viruses including retrovirus, adenovirus, herpes simplex virus (HSV), adeno-associated virus (AAV) and pox virus have been modified to eliminate their toxicity and maintain their high gene transfer capability. The limitations associated with viral vectors, however, in terms of their safety, particularly immunogenicity, and in terms of their limited capacity of transgenic materials, have encouraged researchers to increasingly focus on non-viral vectors as an alternative to viral vectors. Non-viral vectors are generally cationic in nature. They include cationic polymers such as poly(ethylenimine) (PEI) and poly(L-lysine) (PLL), cationic peptides and cationic liposomes. The newly described liposomal preparation LPD (liposomes/protamine/DNA), for example, has shown superiority over conventional liposomes/DNA complexes (lipoplexes). Although non-viral vectors are less efficient than viral ones, they have the advantages of safety, simplicity of preparation and high gene encapsulation capability. This article reviews the most recent studies highlighting the advantages and the limitations of various types of gene delivery systems used in cancer gene therapy.
Collapse
Affiliation(s)
- Anas El-Aneed
- School of Pharmacy, Memorial University of Newfoundland, 300 Prince Philip Dr, St. John's, NL, Canada A1B 3V6.
| |
Collapse
|
47
|
Johnston TP, Kuchimanchi KR, Alur H, Chittchang M, Mitra AK. Inducing a change in the pharmacokinetics and biodistribution of poly-L-lysine in rats by complexation with heparin. J Pharm Pharmacol 2003; 55:1083-90. [PMID: 12956897 DOI: 10.1211/0022357021530] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The aim of our study was to induce changes in the plasma elimination half-life (t(1/2)(elim)), rate and extent of urinary excretion, and biodistribution of a model macromolecule, poly-L-lysine, in rats following complexation with heparin. Male Sprague-Dawley rats were dosed intravenously with either unfractionated [(3)H]heparin, FITC-labelled poly-L-lysine, or an [(3)H]heparin:FITC-labelled poly-L-lysine complex. Serum and blood concentration vs time and urinary excretion profiles were determined as well as the resulting patterns of biodistribution to liver, spleen, kidney, and muscle tissue. While the mean values for the total body clearance of poly-L-lysine and the complex were not significantly different, the volume of distribution and the half-life associated with elimination from the serum were increased greater than 2-fold for the complex compared with free poly-L-lysine. The rate and extent of elimination in the urine followed the relative rank order; heparin > poly-L-lysine> heparin:poly-L-lysine complex. Thirty minutes following intravenous administration, there was significantly more tissue deposition/uptake of the complex in the liver, kidney, and muscle, but not the spleen, when compared with poly-L-lysine administered alone. Complexation of heparin to poly-L-lysine effectively increased the fraction of an administered dose of poly-L-lysine that was deposited in liver, kidney, and muscle tissue. Due to the macromolecular complex being nontoxic and uncharged, potentially it might serve as a suitable carrier for both conventional and peptidic drugs to increase drug distribution to liver, kidney, or muscle tissue.
Collapse
Affiliation(s)
- Thomas P Johnston
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri, Kansas City, MO 64110-2499, USA.
| | | | | | | | | |
Collapse
|
48
|
|
49
|
An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier. Mol Ther 2002. [DOI: 10.1006/mthe.2002.0721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
50
|
Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002; 54:715-58. [PMID: 12204600 DOI: 10.1016/s0169-409x(02)00046-7] [Citation(s) in RCA: 645] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Gene and antisense/ribozyme therapy possesses tremendous potential for the successful treatment of genetically based diseases, such as cancer. Several cancer gene therapy strategies have already been realized in vitro, as well as in vivo. A few have even reached the stage of clinical trials, most of them phase I, while some antisense strategies have advanced to phase II and III studies. Despite this progress, a major problem in exploiting the full potential of cancer gene therapy is the lack of a safe and efficient delivery system for nucleic acids. As viral vectors possess toxicity and immunogenicity, non-viral strategies are becoming more and more attractive. They demonstrate adequate safety profiles, but their rather low transfection efficiency remains a major drawback. This review will introduce the most important cationic polymers used as non-viral vectors for gene and oligonucleotide delivery and will summarize strategies for the targeting of these agents to cancer tissues. Since the low efficiency of this group of vectors can be attributed to specific systemic and subcellular obstacles, these hurdles, as well as strategies to circumvent them, will be discussed. Local delivery approaches of vector/DNA complexes will be summarized and an overview of the principles of anticancer gene and antisense/ribozyme therapy as well as an outline of ongoing clinical trials will be presented.
Collapse
Affiliation(s)
- Thomas Merdan
- Department of Pharmaceutics and Biopharmacy, Philipps University, Ketzerbach 63, 35032 Marburg, Germany
| | | | | |
Collapse
|